Abstract:
PROBLEM TO BE SOLVED: To provide compounds useful to treat hepatitis C (HCV) infections.SOLUTION: In the compounds, the uracil or thymine derivative are linked via a phenylene into either fused 2-ring cyclic system (R6) or alternatively via additional two-atom linker (L) to a 5-6 membered monocycle (R6). Application further discloses polymorphs and pseudopolymorphs of two specific compounds: N-(6(3-t-butyl-5-(2>4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)2-methoxy-phenyl)naphthalen-2-yl)methanesulfonamide and (E)-N-(4(3-t-butyl-5-(2,4-dioxo-3)4-dihydropyrimidin-1(2H)-yl)2-methoxy-styryl-phenyl)methanesulfonamide.
Abstract:
PROBLEM TO BE SOLVED: To provide anti-infective agents and the like, used either in combination with or in lieu of an interferon agent and/or ribavirin.SOLUTION: This invention relates to: (a) compounds and salts thereof that inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.
Abstract:
A novel crystalline cefdinir anhydrate and novel crystalline cefdinir hydrates, ways to make them and use them, compositions comprising them and made with them, and methods of treatment using them are disclosed.
Abstract:
Octahydro-pyrrolo[3,4-b]pyrrole derivatives are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Octahydro-pyrrolo[3,4-b]pyrrole compounds, methods for using such compounds, compositions for making them, and processes for preparing such compounds are disclosed herein.
Abstract:
Disclosed are Uracil or Thymine derivatives of formula (I) examples of which are: (E)-N-(4-(3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide; (E)-N-(4-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide (Z)-N-(4-(2-(3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-2-methoxyphenyl)-1-chlorovinyl)phenyl)methanesulfonamide; (E)-1-(3-tert-butyl-5-(4-fluorostyryl)-4-methoxyphenyl) dihydropyrimidine-2,4(1H,3H)-dione; The compounds are for use in treating Hepatitis C
Abstract:
Раскрытыоктагидропирроло[3,4-b]пиррольныепроизводныеформулы I и II, пригодныедлялечениясостоянийилирасстройств, которыепредотвращаютсяилиоблегчаютсяс помощьюлигандоврецепторагистамина-3.Раскрытыоктагидропирроло[3,4-b]пиррольныесоединения, применениетакихсоединений, композиции, содержащиеэтисоединения, испособыполучениятакихсоединений.
Abstract:
Bis-HCI de ABT-263 y los polimorfos cristalinos del mismo son ingredientes farmacéuticos activos apropiados para composiciones farmacéuticas útiles en el tratamiento de una enfermedad caracterizada por sobre-expresión de una o más proteínas anti-apoptóticas de la familia de BcI-2, por ejemplo cáncer.